X

Stay Connected

Sign Up for Updates

We are creating a place where we can share ideas, provide the perspective of America's biopharmaceutical companies and, most importantly, listen to you.

Cancer medicines cost twice as much at hospitals, study finds

By Katie Koziara  |    January 21, 2020
Cancer medicines cost nearly twice as much in hospital outpatient facilities than in physician offices in the commercial market, according to a new study from the Employee Benefit Research...   Read More

ICYMI: 2019 brings innovative medicines to patients

By Andrew Powaleny  |    January 17, 2020
New reports from the U.S. Food and Drug Administration (FDA) show a total of 56 novel new medicines were approved in 2019. Among these, 48 were approved by the Center for Drug Evaluation and...   Read More

New GAO report: Some hospitals participating in 340B may not be eligible for the program

By Nicole Longo  |    January 14, 2020
The Government Accountability Office (GAO) released a new report on 340B hospital eligibility compliance and made a number of alarming observations that underscore the need for more accountability...   Read More

Nearly 50% of brand medicine spending goes to the supply chain and others

By Holly Campbell  |    January 9, 2020
Nearly 50% of total spending on brand medicines – the sum of all payments made at the pharmacy or paid on a claim to a health care provider – went to the supply chain and other entities in 2018,...   Read More

ICYMI: Cancer death rate declines at record levels thanks to innovative medicines

By Andrew Powaleny  |    January 9, 2020
Each year, the American Cancer Society estimates the number of new cancer cases and deaths that will occur in the United States. For nearly 30 years, the trend towards fewer cancer deaths has been...   Read More

PhRMA comments to Congress on Cures 2.0 call to action

By Anne McDonald Pritchett, PhD  |    December 18, 2019
As new therapies continue to revolutionize the treatment of many diseases, it is positive news that policymakers in Washington are discussing ways to ensure patient access to new treatments and...   Read More

What you need to know about H.R. 3

By Tom Wilbur  |    December 12, 2019
Speaker of the House Nancy Pelosi’s drug pricing proposal, H.R. 3, which is being voted on in the U.S. House of Representatives today, is unprecedented in size and scope. It dramatically expands...   Read More

R&D Focus: Four ways the biopharmaceutical industry leads in delivering new treatments and cures

By Andrew Powaleny  |    December 9, 2019
In recent years, rapid advances in scientific discovery have ushered in a new era of medicine, transforming our ability to treat, and in some cases cure, some of the most challenging diseases,...   Read More

New NHE data: Medicine prices declined, and hospitals were biggest driver of health care spending in 2018

By Holly Campbell  |    December 6, 2019
According to new data from the National Health Expenditures (NHE), retail medicine prices declined by 1% and retail medicine spending grew just 2.5% in 2018. To put that in context, hospital...   Read More

New poll: 76% of voters concerned Speaker Pelosi’s plan would result in fewer new medicines

By Nicole Longo  |    December 5, 2019
The House of Representatives has spent much of this fall focused on Speaker Pelosi’s drug pricing bill, H.R.3, but a recent survey of nearly 2,000 registered voters confirms that H.R.3 is not the...   Read More

Search the Catalyst

View Posts by Topic

see all

Subscribe to Email Updates